

NANOX

Ladenburg Thalmann
Healthcare Conference

September 29, 2022

Introduction

Market and Industry Data and Customer Information

This presentation has been prepared by NANO-X IMAGING LTD ("Nanox" or the "Company") and includes market data and other information from sources believed by the Company to be reliable. For example, industry and market data, including Nanox's own research, and surveys or industry publications and surveys as well as public information about Nanox's customers and discussion with them. Some data are also based on Nanox's good-faith estimates, which are derived from Nanox's review of internal sources as well as the other sources described above. Although Nanox believes these sources are reliable, Nanox has not independently verified that the information is accurate and complete. As a result, you should be aware that market share, ranking and other similar data set forth in this presentation, and estimates and beliefs based on such data may not be reliable.

Disclaimers

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Nanox or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all inclusive or to contain all of the information about the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


Forward-Looking Information Statement

This presentation may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this presentation are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as "can," "might," "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox's ability to complete development of the Nanox System; (ii) Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.Arc and Nanox.CLOUD from regulatory agencies worldwide and its ongoing

compliance with applicable quality standards and regulatory requirements; (iv) Nanox's ability to realize the anticipated benefits of the recent acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox's expectations regarding collaborations with third-parties and their potential benefits; and (viii) Nanox's ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; and (x) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox's actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Nanox's Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this presentation.

Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this presentation to conform these statements to actual results or to changes in the Company's expectations.





NANOX

Together
for better health.





2/3
of the world's
population has no
meaningful **access**
to medical imaging

There is a Radiologist Shortage & Work Overload


A hand on the left side of the frame reaches towards a glowing, digital hand on the right. The digital hand is composed of blue and white particles, giving it a futuristic, data-driven appearance. The background is a solid, deep blue color.

Big Data is underutilized,
resulting in fewer
benefits for patient
outcomes & less efficient
health economics

The Nanox Story

A technological
transformation
from commercial
to medical





The Nanox Solution

Powerful technologies
combined




The Nanox Impact
We aim to build
a global infrastructure
for medical imaging



Hardware Solution INCREASE ACCESSIBILITY



Nanox.SOURCE



Nanox.ARC



Future Products



Concept Device. For Educational Purposes Only.
It is not yet approved for medical use. The device is not available for sale yet.



AI Solution
SUPERPOWER THE DATA



Nanox.Robodiologist



Population Health

Platforms

RADIOLOGIST SERVICES FOR ALL



TELERADIOLOGY




MARKETPLACE

The background features a complex, abstract pattern of overlapping circles and lines in a light blue color against a dark blue background. The pattern consists of numerous thin, intersecting lines that form a grid-like structure within the circular shapes, creating a sense of depth and movement. The circles vary in size and are arranged in a way that they appear to be part of a larger, interconnected network.

Technology Hardware

Technology



From one metal filament heated to 2.000° Celsius, requiring special cooling and rotation mechanics


To a field of 100 Million nano-cones on a silicon chip, emitting digitally controlled electron streams under low voltage



Increase Medical Imaging Accessibility **Nanox.SOURCE**

LICENSE MODEL TO DRIVE PARTNERSHIPS

- For OEMs, we plan to tailor our X-Ray source technology to their specific imaging systems



Increase Medical Imaging Accessibility **Nanox.ARC**

3D DIGITAL MULTI SOURCE SYSTEM

- New breed of medical imaging using revolutionary X-ray source
- Potentially results in lower cost, less complex, and smaller imaging system
- Aims to democratize global availability



Concept Device. For Educational Purposes Only.
It is not yet approved for medical use. The device is not available for sale yet.






Technology
AI



Large data repository

Tools and automated workflows to support data serving



Heterogeneous Data • Ethnicity • Age
Regulatory Framework • 10 FDA Clearances • 11 CE Marks / Health

The Power of AI in Medical Imaging Robodiologist

DEVELOPMENT OF AN AUTOMATED RADIOLOGIST SOLUTION

Development of artificial intelligence would allow the radiologists to focus on the abnormal studies and prioritize the normal cases, which we believe will improve patient healthcare


Clients
MSaaS Partners



CHEST



EXTREMITIES



The Next AI Revolution Population Health

90% OF THE US \$3.5 TRILLION
HEALTHCARE FUND SPEND IS FOR
CHRONIC CONDITIONS*


- We believe AI will be able to “mine” information of rich images to identify patients with undiagnosed or underdiagnosed medical conditions
- We can provide screening for chronic medical conditions, on pre-existing data to detect disease, help promote health and lower costs

Clients

Integrated Delivery Networks (IDNs),
Commercial Payers and Pharmaceutical
Companies, Governmental Health Ministries

CDC Centers for Disease Control and Prevention

FDA
CLEARED



BONE HEALTH
SOLUTION

Vertebral Compression
Fractures

CHEST / ABDOMEN CT


FDA
CLEARED



CARDIAC
SOLUTION

Coronary Calcium
Detection

CHEST / NON-GATED CT



Fatty Liver





**NANOX
ECO - SYSTEM**



Concept Device. For Educational Purposes Only.
It is not yet approved for medical use. The device is not available for sale yet.

BUSINESS MODEL


Nanox blue ocean

We do not intend to compete over market share,
we plan to expand the total market

We target Urgent Care
units ,outpatient clinics,
rural areas, countries
with limited medical
imaging availability

We believe the CAPEX
market of hospitals,
medical centers and
clinics will migrate to an
**OPEX service-based
model** over time





- Closed pre-sale agreements
- In negotiations

At 20 scans per day, and \$14 per scan revenue to Nanox and 23 days per month, the MSaaS model potentially generates approx \$500 million in recurring revenues annually **assuming 6,850 contracted systems are deployed and operational.**

Taiwan / Singapore / Italy / Russia / Belarus / Australia / Spain / New Zealand / Norway / Brazil / S. Africa / Mexico / Guatemala / Nigeria / Chile /Ghana

SCANS	7	Minimum scans per day per system
PER DAY	20	Nanox operational objective



Business Model

- Pay-per-scan service business model
- Nanox covers CAPEX investment in systems and deployment

• **\$40 total cost per scan as a global average based on current contracts**

• **Nanox revenue: \$14 (out of the \$40) per scan based on current contracts**

-
- Contracting regional service providers for marketing and operation of the service

- Current contracts provide a minimum annual service fee for 7 scans per day per system against regional exclusivity

-
- Total number of systems deployed may vary as per financing and final unit cost

-
- Price-per-scan will vary based on regional economics

-
- Minimum annual service fees will be backed by a standby letter of credit or financial guarantee upon receipt of local regulatory approval and acceptance test.

OEMs

- For OEMs, we plan to tailor our X-Ray source technology to their specific imaging systems
- Expect to charge a one-time licensing fee upfront
- Receive recurring royalty payments for each system sold.

Security / Manufacturing

We believe our Proprietary technology - Nanox MEMS offers a wide range of applications in different industries, such as security, manufacturing, and more.

FINANCE

NANOX – Q2 2022 Financial highlights

\$ 126.7M ¹

Cash
balance

176

Worldwide
FTE

\$ 42.9 M ²

PP&E

\$ 2.2M YTD \$4.0M

Generated
revenue

52.2 M

Outstanding
shares

59.6 M

Outstanding shares
on a fully diluted basis

(1) Includes 75.0\$M short and L/T Marketable Securities

(2) Mainly due to purchasing of machinery and equipment of the semi conductor and tube manufacturing lines in NK.



NANOX

This is how WE
accomplish our mission.
**Scan globally to
protect one's health.**





NANOX

Thank You!